Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).

被引：4
|
作者：
Lonial, Sagar
Dimopoulos, Meletios A.
Weisel, Katja C.
White, Darrell
Moreau, Philippe
Mateos, Maria-Victoria
Miguel, Jesus San
Anderson, Kenneth Carl
Shpilberg, Ofer
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Magen, Hila
Belch, Andrew
Reece, Donna Ellen
Beksac, Meral
Mekan, Sabeen
Sy, Oumar
Singhal, Anil K.
Richardson, Paul G.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.8028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8028
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan
    Takezako, Naoki
    Ohta, Kensuke
    Handa, Hiroshi
    Hori, Mitsuo
    Kinoshita, Gen
    Shelat, Suresh
    Miyoshi, Masafumi
    Kubo, Kohmei
    BLOOD, 2017, 130
  • [32] Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)
    Bahlis, Nizar
    Dimopoulos, Meletios A.
    White, Darrell J.
    Benboubker, Lotfi
    Cook, Gordon
    Leiba, Merav
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Moreau, Philippe
    Krevvata, Maria
    Chiu, Christopher
    Qin, Xiang
    Okonkwo, Linda
    Trivedi, Sonali
    Qi, Ming
    San-Miguel, Jesus F.
    BLOOD, 2018, 132
  • [33] Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
    Bruzzese, Antonella
    Derudas, Daniele
    Galli, Monica
    Martino, Enrica Antonia
    Rocco, Stefano
    Conticello, Concetta
    Califano, Catello
    Giuliani, Nicola
    Mangiacavalli, Silvia
    Farina, Giuliana
    Lombardo, Alessandra
    Brunori, Marino
    Rossi, Elena
    Antonioli, Elisabetta
    Ria, Roberto
    Zambello, Renato
    Di Renzo, Nicola
    Mele, Giuseppe
    Marcacci, Gianpaolo
    Pietrantuono, Giuseppe
    Palumbo, Gaetano
    Cascavilla, Nicola
    Cerchione, Claudio
    Belotti, Angelo
    Criscuolo, Clelia
    Uccello, Giuseppina
    Curci, Paola
    Vigna, Ernesto
    Mendicino, Francesco
    Iaccino, Enrico
    Mimmi, Selena
    Botta, Cirino
    Vincelli, Donatella
    Sgherza, Nicola
    Bonalumi, Angela
    Cupelli, Luca
    Stocchi, Raffaella
    Martino, Massimo
    Ballanti, Stelvio
    Gangemi, Dominella
    Gagliardi, Alfredo
    Gamberi, Barbara
    Pompa, Alessandra
    Tripepi, Giovanni
    Frigeri, Ferdinando
    Consoli, Ugo
    Bringhen, Sara
    Zamagni, Elena
    Patriarca, Francesca
    Stefano, Valerio
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 704 - 715
  • [34] Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study
    Hori, Mitsuo
    Takezako, Naoki
    Sunami, Kazutaka
    Ito, Shigeki
    Kuroda, Junya
    Popa-McKiver, Mihaela
    Jou, Ying-Ming
    Shelat, Suresh G.
    Miyoshi, Masafumi
    Suzuki, Kenshi
    BLOOD, 2018, 132
  • [35] Elotuzumab plus lenalidomide and dexamethasone (ELd) in relapsed/refractory multiple myeloma (RRMM): ELOQUENT-2 post-hoc analysis of progression-free survival (PFS), tumor regrowth by time from diagnosis and prior lines of therapy, and median duration of response (DOR)
    Weisel, K.
    Dimopoulos, M. A.
    Palumbo, A.
    Richardson, P.
    Mateos, M. -, V
    Moreau, P.
    Gupta, M.
    Sheng, J.
    Passey, C.
    Sy, O.
    Katz, J.
    Lonial, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 223 - 223
  • [36] ELOTUZUMAB plus LENALIDOMIDE/DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: ELOQUENT-2 POST-HOC ANALYSIS OF PFS AND TUMOR REGROWTH BY TIME FROM DIAGNOSIS AND PRIOR LINES OF THERAPY
    Dimopoulos, M. A.
    Palumbo, A.
    Weisel, K.
    Richardson, P.
    Mateos, M. V.
    Moreau, P.
    Gupta, M.
    Sheng, J.
    Passey, C.
    Sy, O.
    Katz, J.
    Lonial, S.
    HAEMATOLOGICA, 2016, 101 : 85 - 85
  • [37] ELOTUZUMAB IN COMBINATION WITH LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE 1/2 STUDY
    Lonial, S.
    Vij, R.
    Harousseau, J. L.
    Facon, T.
    Moreau, P.
    Mazumder, A.
    Kaufman, J.
    Leleu, X.
    Tsao, C.
    Fry, J.
    Singhal, A.
    Jagganath, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 157 - 158
  • [38] A RANDOMIZED PHASE 2 STUDY OF ELOTUZUMAB WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Richardson, P.
    Jakubowiak, A.
    Jagannath, S.
    Raab, M.
    Facon, T.
    Vij, R.
    Reece, D.
    White, D.
    Benboubker, L.
    Zonder, J.
    Rossi, J. F.
    Tsao, C.
    Parli, T.
    Kroog, G.
    Singhal, A.
    Lonial, S.
    HAEMATOLOGICA, 2012, 97 : 474 - 474
  • [39] A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raab, Marc S.
    Facon, Thierry
    Vij, Ravi
    Moreau, Philippe
    Reece, Donna E.
    White, Darrell J.
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Rossi, Jean-Francois
    Tsao, Claire
    Parli, Teresa
    Kroog, Glenn
    Singhal, Anil K.
    Richardson, Paul G.
    BLOOD, 2011, 118 (21) : 141 - 142
  • [40] Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma ( RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial
    Weisel, Katja
    Dimopoulos, Meletios A.
    San-Miguel, Jesus
    Paner, Agne
    Engelhardt, Monika
    Taylor, Fiona
    Lord-Bessen, Jennifer
    Yao, David
    Yip, Christine
    Greenwood, Mike
    Tang, Jackson
    Cavo, Michele
    BLOOD, 2021, 138
12345